APO Research
Talk to an analyst

APO RESEARCH · REPORT

Irritable Bowel Syndrome (IBS)

Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.

Selected research

Market Analysis & Forecast

Global Irritable Bowel Syndrome (IBS) Market Analysis and Forecast 2026-2032

26 December 2025191 pages

Choose your research edition.

Industry ResearchIrritable Bowel Syndrome (IBS) Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Irritable Bowel Syndrome (IBS) Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Irritable Bowel Syndrome (IBS) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Irritable Bowel Syndrome (IBS) Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Irritable Bowel Syndrome (IBS) Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.

North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.

Report Includes

Read the full market overview

This report presents an overview of global market for Irritable Bowel Syndrome (IBS), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Irritable Bowel Syndrome (IBS), also provides the revenue of main regions and countries. Of the upcoming market potential for Irritable Bowel Syndrome (IBS), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Irritable Bowel Syndrome (IBS) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Irritable Bowel Syndrome (IBS) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Irritable Bowel Syndrome (IBS) revenue, projected growth trends, production technology, application and end-user industry.

Irritable Bowel Syndrome (IBS) Segment by Company

Bausch Health

Allergan

Takeda

Sucampo Pharmaceuticals (Mallinckrodt)

Sebela Pharmaceuticals Inc

Astellas Pharmaceuticals

Irritable Bowel Syndrome (IBS) Segment by Type

IBS-D Drug

IBS-C Drug

Others

Irritable Bowel Syndrome (IBS) Segment by Application

Women

Men

Irritable Bowel Syndrome (IBS) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome (IBS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome (IBS) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome (IBS).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Irritable Bowel Syndrome (IBS) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Irritable Bowel Syndrome (IBS) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Irritable Bowel Syndrome (IBS) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Irritable Bowel Syndrome (IBS) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. IBS-D Drug Major Player Table 3. IBS-C Drug Major Player Table 4. Others Major Player Table 5. Global Irritable Bowel Syndrome (IBS) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Women Major Player Table 7. Men Major Player Table 8. Irritable Bowel Syndrome (IBS) Industry Trends Table 9. Irritable Bowel Syndrome (IBS) Industry Drivers Table 10. Irritable Bowel Syndrome (IBS) Industry Opportunities and Challenges Table 11. Irritable Bowel Syndrome (IBS) Industry Restraints Table 12. Global Irritable Bowel Syndrome (IBS) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Irritable Bowel Syndrome (IBS) Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Irritable Bowel Syndrome (IBS) Market Share by Region (2021-2026) Table 15. Global Irritable Bowel Syndrome (IBS) Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Irritable Bowel Syndrome (IBS) Market Share by Region (2027-2032) Table 17. Global Irritable Bowel Syndrome (IBS) Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Players (2021-2026) Table 19. Global Irritable Bowel Syndrome (IBS) Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Irritable Bowel Syndrome (IBS) Key Players Headquarters & Area Served Table 21. Global Irritable Bowel Syndrome (IBS) Players, Product Type & Application Table 22. Global Irritable Bowel Syndrome (IBS) Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Irritable Bowel Syndrome (IBS) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Irritable Bowel Syndrome (IBS) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Irritable Bowel Syndrome (IBS) Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2021-2026) Table 29. Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2027-2032) Table 30. Global Irritable Bowel Syndrome (IBS) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Irritable Bowel Syndrome (IBS) Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2021-2026) Table 34. Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2027-2032) Table 35. Bausch Health Company Information Table 36. Bausch Health Business Overview Table 37. Bausch Health Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Bausch Health Irritable Bowel Syndrome (IBS) Product Portfolio Table 39. Bausch Health Recent Development Table 40. Allergan Company Information Table 41. Allergan Business Overview Table 42. Allergan Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Allergan Irritable Bowel Syndrome (IBS) Product Portfolio Table 44. Allergan Recent Development Table 45. Takeda Company Information Table 46. Takeda Business Overview Table 47. Takeda Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Takeda Irritable Bowel Syndrome (IBS) Product Portfolio Table 49. Takeda Recent Development Table 50. Sucampo Pharmaceuticals (Mallinckrodt) Company Information Table 51. Sucampo Pharmaceuticals (Mallinckrodt) Business Overview Table 52. Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Product Portfolio Table 54. Sucampo Pharmaceuticals (Mallinckrodt) Recent Development Table 55. Sebela Pharmaceuticals Inc Company Information Table 56. Sebela Pharmaceuticals Inc Business Overview Table 57. Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Product Portfolio Table 59. Sebela Pharmaceuticals Inc Recent Development Table 60. Astellas Pharmaceuticals Company Information Table 61. Astellas Pharmaceuticals Business Overview Table 62. Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio Table 64. Astellas Pharmaceuticals Recent Development Table 65. North America Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2026) & (US$ Million) Table 66. North America Irritable Bowel Syndrome (IBS) Revenue by Type (2027-2032) & (US$ Million) Table 67. North America Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2026) & (US$ Million) Table 68. North America Irritable Bowel Syndrome (IBS) Revenue by Application (2027-2032) & (US$ Million) Table 69. North America Irritable Bowel Syndrome (IBS) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 70. North America Irritable Bowel Syndrome (IBS) Revenue by Country (2021-2026) & (US$ Million) Table 71. North America Irritable Bowel Syndrome (IBS) Revenue by Country (US$ Million) & (2027-2032) Table 72. Europe Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2026) & (US$ Million) Table 73. Europe Irritable Bowel Syndrome (IBS) Revenue by Type (2027-2032) & (US$ Million) Table 74. Europe Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2026) & (US$ Million) Table 75. Europe Irritable Bowel Syndrome (IBS) Revenue by Application (2027-2032) & (US$ Million) Table 76. Europe Irritable Bowel Syndrome (IBS) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 77. Europe Irritable Bowel Syndrome (IBS) Revenue by Country (2021-2026) & (US$ Million) Table 78. Europe Irritable Bowel Syndrome (IBS) Revenue by Country (US$ Million) & (2027-2032) Table 79. China Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2026) & (US$ Million) Table 80. China Irritable Bowel Syndrome (IBS) Revenue by Type (2027-2032) & (US$ Million) Table 81. China Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2026) & (US$ Million) Table 82. China Irritable Bowel Syndrome (IBS) Revenue by Application (2027-2032) & (US$ Million) Table 83. Asia Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2026) & (US$ Million) Table 84. Asia Irritable Bowel Syndrome (IBS) Revenue by Type (2027-2032) & (US$ Million) Table 85. Asia Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2026) & (US$ Million) Table 86. Asia Irritable Bowel Syndrome (IBS) Revenue by Application (2027-2032) & (US$ Million) Table 87. Asia Irritable Bowel Syndrome (IBS) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Asia Irritable Bowel Syndrome (IBS) Revenue by Region (US$ Million) & (2021-2026) Table 89. Asia Irritable Bowel Syndrome (IBS) Revenue by Region (US$ Million) & (2027-2032) Table 90. SAMEA Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2026) & (US$ Million) Table 91. SAMEA Irritable Bowel Syndrome (IBS) Revenue by Type (2027-2032) & (US$ Million) Table 92. SAMEA Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2026) & (US$ Million) Table 93. SAMEA Irritable Bowel Syndrome (IBS) Revenue by Application (2027-2032) & (US$ Million) Table 94. SAMEA Irritable Bowel Syndrome (IBS) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. SAMEA Irritable Bowel Syndrome (IBS) Revenue by Country (2021-2026) & (US$ Million) Table 96. SAMEA Irritable Bowel Syndrome (IBS) Revenue by Country (US$ Million) & (2027-2032) Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Irritable Bowel Syndrome (IBS) Image Figure 2. Global Irritable Bowel Syndrome (IBS) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Irritable Bowel Syndrome (IBS) Market Size Share 2021 VS 2025 VS 2032 Figure 4. IBS-D Drug Image Figure 5. IBS-C Drug Image Figure 6. Others Image Figure 7. Global Irritable Bowel Syndrome (IBS) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Irritable Bowel Syndrome (IBS) Market Size Share 2021 VS 2025 VS 2032 Figure 9. Women Image Figure 10. Men Image Figure 11. Global Irritable Bowel Syndrome (IBS) Market Size (US$ Million) & (2021-2032) Figure 12. Global Irritable Bowel Syndrome (IBS) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Irritable Bowel Syndrome (IBS) Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Irritable Bowel Syndrome (IBS) Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Irritable Bowel Syndrome (IBS) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Irritable Bowel Syndrome (IBS) Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2021-2032) Figure 19. Global Irritable Bowel Syndrome (IBS) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2021-2032) Figure 22. North America Irritable Bowel Syndrome (IBS) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Irritable Bowel Syndrome (IBS) Revenue Share by Type (2021-2032) Figure 24. North America Irritable Bowel Syndrome (IBS) Revenue Share by Application (2021-2032) Figure 25. North America Irritable Bowel Syndrome (IBS) Revenue Share by Country (2021-2032) Figure 26. United States Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Irritable Bowel Syndrome (IBS) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Irritable Bowel Syndrome (IBS) Revenue Share by Type (2021-2032) Figure 31. Europe Irritable Bowel Syndrome (IBS) Revenue Share by Application (2021-2032) Figure 32. Europe Irritable Bowel Syndrome (IBS) Revenue Share by Country (2021-2032) Figure 33. Germany Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Irritable Bowel Syndrome (IBS) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Irritable Bowel Syndrome (IBS) Revenue Share by Type (2021-2032) Figure 43. China Irritable Bowel Syndrome (IBS) Revenue Share by Application (2021-2032) Figure 44. Asia Irritable Bowel Syndrome (IBS) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Irritable Bowel Syndrome (IBS) Revenue Share by Type (2021-2032) Figure 46. Asia Irritable Bowel Syndrome (IBS) Revenue Share by Application (2021-2032) Figure 47. Asia Irritable Bowel Syndrome (IBS) Revenue Share by Region (2021-2032) Figure 48. Japan Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Irritable Bowel Syndrome (IBS) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Irritable Bowel Syndrome (IBS) Revenue Share by Type (2021-2032) Figure 56. SAMEA Irritable Bowel Syndrome (IBS) Revenue Share by Application (2021-2032) Figure 57. SAMEA Irritable Bowel Syndrome (IBS) Revenue Share by Country (2021-2032) Figure 58. Brazil Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Irritable Bowel Syndrome (IBS) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • IBS-D Drug
  • IBS-C Drug
  • Others
Applications
  • Women
  • Men
Companies covered
  • Bausch Health
  • Allergan
  • Takeda
  • Sucampo Pharmaceuticals (Mallinckrodt)
  • Sebela Pharmaceuticals Inc
  • Astellas Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Irritable Bowel Syndrome (IBS) Market by Type
  3. 1.2.1 Global Irritable Bowel Syndrome (IBS) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 IBS-D Drug
  5. 1.2.3 IBS-C Drug
  6. 1.2.4 Others
  7. 1.3 Irritable Bowel Syndrome (IBS) Market by Application
  8. 1.3.1 Global Irritable Bowel Syndrome (IBS) Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Women
  10. 1.3.3 Men
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Irritable Bowel Syndrome (IBS) Market Dynamics
  1. 2.1 Irritable Bowel Syndrome (IBS) Industry Trends
  2. 2.2 Irritable Bowel Syndrome (IBS) Industry Drivers
  3. 2.3 Irritable Bowel Syndrome (IBS) Industry Opportunities and Challenges
  4. 2.4 Irritable Bowel Syndrome (IBS) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Irritable Bowel Syndrome (IBS) Market Perspective (2021-2032)
  2. 3.2 Global Irritable Bowel Syndrome (IBS) Growth Trends by Region
  3. 3.2.1 Global Irritable Bowel Syndrome (IBS) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Irritable Bowel Syndrome (IBS) Market Size by Region (2021-2026)
  5. 3.2.3 Global Irritable Bowel Syndrome (IBS) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Irritable Bowel Syndrome (IBS) Revenue by Players
  2. 4.1.1 Global Irritable Bowel Syndrome (IBS) Revenue by Players (2021-2026)
  3. 4.1.2 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Irritable Bowel Syndrome (IBS) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Irritable Bowel Syndrome (IBS) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Irritable Bowel Syndrome (IBS) Key Players Headquarters & Area Served
  7. 4.4 Global Irritable Bowel Syndrome (IBS) Players, Product Type & Application
  8. 4.5 Global Irritable Bowel Syndrome (IBS) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Irritable Bowel Syndrome (IBS) Market CR5 and HHI
  11. 4.6.3 2025 Irritable Bowel Syndrome (IBS) Tier 1, Tier 2, and Tier 3
5 Irritable Bowel Syndrome (IBS) Market Size by Type
  1. 5.1 Global Irritable Bowel Syndrome (IBS) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2032)
  3. 5.3 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2021-2032)
6 Irritable Bowel Syndrome (IBS) Market Size by Application
  1. 6.1 Global Irritable Bowel Syndrome (IBS) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2032)
  3. 6.3 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Bausch Health
  2. 7.1.1 Bausch Health Company Information
  3. 7.1.2 Bausch Health Business Overview
  4. 7.1.3 Bausch Health Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Bausch Health Irritable Bowel Syndrome (IBS) Product Portfolio
  6. 7.1.5 Bausch Health Recent Developments
  7. 7.2 Allergan
  8. 7.2.1 Allergan Company Information
  9. 7.2.2 Allergan Business Overview
  10. 7.2.3 Allergan Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Allergan Irritable Bowel Syndrome (IBS) Product Portfolio
  12. 7.2.5 Allergan Recent Developments
  13. 7.3 Takeda
  14. 7.3.1 Takeda Company Information
  15. 7.3.2 Takeda Business Overview
  16. 7.3.3 Takeda Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Takeda Irritable Bowel Syndrome (IBS) Product Portfolio
  18. 7.3.5 Takeda Recent Developments
  19. 7.4 Sucampo Pharmaceuticals (Mallinckrodt)
  20. 7.4.1 Sucampo Pharmaceuticals (Mallinckrodt) Company Information
  21. 7.4.2 Sucampo Pharmaceuticals (Mallinckrodt) Business Overview
  22. 7.4.3 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Product Portfolio
  24. 7.4.5 Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments
  25. 7.5 Sebela Pharmaceuticals Inc
  26. 7.5.1 Sebela Pharmaceuticals Inc Company Information
  27. 7.5.2 Sebela Pharmaceuticals Inc Business Overview
  28. 7.5.3 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Product Portfolio
  30. 7.5.5 Sebela Pharmaceuticals Inc Recent Developments
  31. 7.6 Astellas Pharmaceuticals
  32. 7.6.1 Astellas Pharmaceuticals Company Information
  33. 7.6.2 Astellas Pharmaceuticals Business Overview
  34. 7.6.3 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio
  36. 7.6.5 Astellas Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Irritable Bowel Syndrome (IBS) Revenue (2021-2032)
  2. 8.2 North America Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2032)
  3. 8.2.1 North America Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2026)
  4. 8.2.2 North America Irritable Bowel Syndrome (IBS) Revenue by Type (2027-2032)
  5. 8.3 North America Irritable Bowel Syndrome (IBS) Revenue Share by Type (2021-2032)
  6. 8.4 North America Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2032)
  7. 8.4.1 North America Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2026)
  8. 8.4.2 North America Irritable Bowel Syndrome (IBS) Revenue by Application (2027-2032)
  9. 8.5 North America Irritable Bowel Syndrome (IBS) Revenue Share by Application (2021-2032)
  10. 8.6 North America Irritable Bowel Syndrome (IBS) Revenue by Country
  11. 8.6.1 North America Irritable Bowel Syndrome (IBS) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Irritable Bowel Syndrome (IBS) Revenue by Country (2021-2026)
  13. 8.6.3 North America Irritable Bowel Syndrome (IBS) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Irritable Bowel Syndrome (IBS) Revenue (2021-2032)
  2. 9.2 Europe Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Irritable Bowel Syndrome (IBS) Revenue by Type (2027-2032)
  5. 9.3 Europe Irritable Bowel Syndrome (IBS) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Irritable Bowel Syndrome (IBS) Revenue by Application (2027-2032)
  9. 9.5 Europe Irritable Bowel Syndrome (IBS) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Irritable Bowel Syndrome (IBS) Revenue by Country
  11. 9.6.1 Europe Irritable Bowel Syndrome (IBS) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Irritable Bowel Syndrome (IBS) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Irritable Bowel Syndrome (IBS) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Irritable Bowel Syndrome (IBS) Revenue (2021-2032)
  2. 10.2 China Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2032)
  3. 10.2.1 China Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2026)
  4. 10.2.2 China Irritable Bowel Syndrome (IBS) Revenue by Type (2027-2032)
  5. 10.3 China Irritable Bowel Syndrome (IBS) Revenue Share by Type (2021-2032)
  6. 10.4 China Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2032)
  7. 10.4.1 China Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2026)
  8. 10.4.2 China Irritable Bowel Syndrome (IBS) Revenue by Application (2027-2032)
  9. 10.5 China Irritable Bowel Syndrome (IBS) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Irritable Bowel Syndrome (IBS) Revenue (2021-2032)
  2. 11.2 Asia Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Irritable Bowel Syndrome (IBS) Revenue by Type (2027-2032)
  5. 11.3 Asia Irritable Bowel Syndrome (IBS) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Irritable Bowel Syndrome (IBS) Revenue by Application (2027-2032)
  9. 11.5 Asia Irritable Bowel Syndrome (IBS) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Irritable Bowel Syndrome (IBS) Revenue by Country
  11. 11.6.1 Asia Irritable Bowel Syndrome (IBS) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Irritable Bowel Syndrome (IBS) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Irritable Bowel Syndrome (IBS) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Irritable Bowel Syndrome (IBS) Revenue (2021-2032)
  2. 12.2 SAMEA Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Irritable Bowel Syndrome (IBS) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Irritable Bowel Syndrome (IBS) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Irritable Bowel Syndrome (IBS) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Irritable Bowel Syndrome (IBS) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Irritable Bowel Syndrome (IBS) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Irritable Bowel Syndrome (IBS) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Irritable Bowel Syndrome (IBS) Revenue by Country
  11. 12.6.1 SAMEA Irritable Bowel Syndrome (IBS) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Irritable Bowel Syndrome (IBS) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Irritable Bowel Syndrome (IBS) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst